Sickle Cell Crisis and Staff Stigma
28-year-old woman with sickle cell disease (HbSS) is admitted with a vaso-occlusive crisis. She reports 9/10 pain in back and legs. She is on chronic hydroxyurea and has had four admissions in 6 months. Her outpatient regimen is morphine sulfate extended-release 30 mg twice daily plus oxycodone 10 mg every 4 hours as needed; she says she needs 'much more' in the hospital. The admitting resident writes 'drug-seeking' in the chart and plans to give only ketorolac. She has a history of acute chest syndrome and a ventricular septal defect.
1. Why is the resident's plan inappropriate, and what is the appropriate immediate approach?
Read the worked answer
The plan is inappropriate because sickle cell vaso-occlusive pain is real, severe, and undertreated pain can cause suffering, delayed care, and complications. Labeling her as drug-seeking is stigmatizing and can lead to inadequate analgesia; ketorolac alone is insufficient for a 9/10 crisis and carries renal and gastrointestinal risk, especially if she is dehydrated. The appropriate approach is rapid assessment and prompt parenteral opioid therapy, ideally with a PCA, while treating dehydration, hypoxemia, and any precipitating cause. I would involve hematology and the pain service early, and I would not require her to prove her pain. At the same time, I would assess her baseline opioid tolerance and screen for opioid use disorder, because tolerance is expected with chronic therapy but addiction is a separate diagnosis. The two are not mutually exclusive, and neither justifies withholding acute pain treatment.
2. Design an analgesic plan for the first 24 hours, including dosing and adjuvants.
Read the worked answer
Her home regimen is morphine ER 60 mg/day plus up to 60 mg/day of oxycodone, so her baseline MEDD is about 120 mg. For an acute crisis, I would start a PCA with hydromorphone or morphine. If using hydromorphone, a reasonable approach is a demand dose of 0.2–0.4 mg every 10–15 minutes with a low basal infusion at 50–80% of her calculated home requirement, but only because she is opioid-tolerant; for an opioid-naive patient, I would not use a basal. I would reassess pain and sedation every 1–2 hours and titrate. Add scheduled acetaminophen and consider low-dose ketamine (e.g., 0.1–0.3 mg/kg/h) for refractory pain, with monitoring. Avoid meperidine. NSAIDs can be used briefly if renal function is normal, but not as monotherapy. Continue hydroxyurea, hydration, and incentive spirometry. Have naloxone available, and start a bowel regimen.
3. How would you address the team's stigma and ensure a safe discharge plan?
Read the worked answer
I would speak with the resident privately and explain that 'drug-seeking' is a damaging label and that sickle cell pain requires aggressive treatment. I would share the evidence that undertreatment increases morbidity and that tolerance is expected. I would ask the team to use neutral language and to document objective findings and the treatment plan. I would involve hematology, pain medicine, and social work in a coordinated plan, and I would screen for opioid use disorder without assuming it. For discharge, I would reconcile her opioid doses, ensure she has a follow-up appointment within a week, provide naloxone, and give a written crisis plan that specifies what to do and whom to call. I would also ask her what has helped in prior admissions and include her in the plan.